 | ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
 | ||||||||||||
 | ||||||||||||
 | ||||||||||||
| ||||||||||||||
|
|
Click on the titles below for current clinical trials information and eligibility criteria. Marqibo® (vincristine sulfate injection, OPTISOME™) Phase I: Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction Phase II: Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia (rALLy) Phase II: Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Alocrest™ (vinorelbine tartrate injection, OPTISOME™) Phase I: Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease For more information, prospective patients or their physicians should send an email to info@hanabiosciences.com | ||||||||||||
| ||||||||||||||
| ||||||||||||||
